

## Recombinant Human S100P/S100E Protein

**Catalog Number:** PKSH030800

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Species</b>	Human
<b>Source</b>	E.coli-derived Human S100P/S100E protein Met 1-Lys 95
<b>Calculated MW</b>	10.4 kDa
<b>Accession</b>	P25815
<b>Bio-activity</b>	Not validated for activity

### Properties

<b>Purity</b>	> 97 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	Please contact us for more information.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
<b>Reconstitution</b>	Please refer to the specific buffer information in the printed manual. Please refer to the printed manual for detailed information.

### Data



> 97 % as determined by reducing SDS-PAGE.

### Background

### For Research Use Only

Protein S100-P; also known as Protein S100-E; S100 calcium-binding protein P; S100P and S100E; is a nucleus and cytoplasm protein which belongs to the S-100 family. S100P / S100E contains two EF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction; protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas; whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target; and could also serve as a biomarker for aggressive; hormone-refractory and metastatic prostate cancer.